Vaccination efficacy in patients with chronic lymphocytic leukemia

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Chronic Lymphocytic Leukemia - Cancer Stat Facts [Internet]. SEER. 2021. https://seer.cancer.gov/statfacts/html/clyl.html
   Google Scholar
• Whitaker JA, Parikh SA, Shanafelt TD, et al. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021;39(7):1122–1130.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Infections in patients with leukemia and lymphoma. In: Stosor V, Zembower TR, editors. Infect complicat cancer patients. Cham: Springer International Publishing; 2014. p. 319–349.
   Google Scholar
• Sinisalo M, Aittoniemi J, Käyhty H, et al. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(4):649–652.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26–e35.
   PubMed Web of Science ®Google Scholar
• Jin P, Li J, Pan H, et al. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):48.
   PubMed Web of Science ®Google Scholar
• Whitaker JA, Shanafelt TD, Poland GA, et al. Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014;12(7):440–450.
   PubMedGoogle Scholar
• Alexander KE, Tong PL, Macartney K, et al. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890–3893.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Infectious Diseases Society of America, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–e100.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Gong I, Betschel SD, et al. Vaccine response following anti-CD20 therapy: a systematic reivew and Meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624–2643.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic leukemia (Version 3.2022). 2022. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
   Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and Meta-analysis. Leuk Lymphoma. 2009;50(5):764–772.
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236–252.
   PubMed Web of Science ®Google Scholar
• Biernat MM, Kolasińska A, Kwiatkowski J, et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses. 2021;13(3):436.
   PubMed Web of Science ®Google Scholar
• Dougan M, Nirula A, Azizad M, et al. BLAZE-1 investigators. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med. 2021;385(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Trial Investigators, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, PROVENT Study Group, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188–2200.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, COMET-ICE Investigators, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950.
   PubMed Web of Science ®Google Scholar
• Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511–1518.
   PubMed Web of Science ®Google Scholar
• FastStats [Internet]. 2021. https://www.cdc.gov/nchs/fastats/flu.htm.
   Google Scholar
• Abdel-Rahman O. Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study. Expert Rev Respir Med. 2021;15(3):393–401.
   PubMed Web of Science ®Google Scholar
• Freedman M, Kroger A, Hunter P, for the Advisory Committee on Immunization Practices, et al. Recommended adult immunization schedule, United States, 2020*. Ann Intern Med. 2020;172(5):337.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of High-Dose versus StandardDose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
   PubMed Web of Science ®Google Scholar
• Nauta JJP, Beyer WEP, Osterhaus ADME. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals. 2009;37(4):216–221.
   PubMed Web of Science ®Google Scholar
• Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccines Immunother. 2013;9(2):405–408.
   PubMed Web of Science ®Google Scholar
• Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol. 2014;8:CMO.S13774.
   Google Scholar
• Vinograd I, Eliakim-Raz N, Farbman L, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients: Influenza vaccine in cancer patients. Cancer. 2013;119(22):4028–4035.
   PubMed Web of Science ®Google Scholar
• Douglas AP, Trubiano JA, Barr I, et al. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397–e399.
   PubMed Web of Science ®Google Scholar
• van der Velden AMT, Mulder AHL, Hartkamp A, et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12(5):420–424.
   PubMedGoogle Scholar
• Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2(12):1656–1657.
   PubMed Web of Science ®Google Scholar
• Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005;3(4):214–220.
   PubMedGoogle Scholar
• Fiorcari S, Maffei R, Audrito V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016;7(40):65968–65981.
   PubMedGoogle Scholar
• Parry HM, Mirajkar N, Cutmore N, et al. Long-Term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia. Front Immunol. 2019;10:2832.
   PubMed Web of Science ®Google Scholar
• Ide Y, Imamura Y, Ohfuji S, et al. Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies. Hum Vaccin Immunother. 2014;10(8):2387–2394.
   PubMed Web of Science ®Google Scholar
• Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–6771.
   PubMed Web of Science ®Google Scholar
• Lindström V, Aittoniemi J, Salmenniemi U, et al. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2019;15(12):2910–2913.
   PubMed Web of Science ®Google Scholar
• Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the swedish CLL group. Vaccine. 2018;36(25):3701–3707.
   PubMed Web of Science ®Google Scholar
• Lindström V, Aittoniemi J, Salmenniemi U, et al. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2018;14(6):1471–1474.
   PubMed Web of Science ®Google Scholar
• Andrick B, Alwhaibi A, DeRemer DL, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182(5):712–714.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737–746.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent pneumococcal conjugate vaccine and 20-Valent pneumococcal conjugate vaccine among U.S. Adults: Updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–117.
   PubMed Web of Science ®Google Scholar
• Ermlich SJ, Andrews CP, Folkerth S, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018;36(45):6875–6882.
   PubMed Web of Science ®Google Scholar
• Essink B, Sabharwal C, Xu X, et al. 3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older. Open Forum Infect Dis. 2020;7(Supplement_1):S2–S2.
   Google Scholar
• Dagnew AF, Ilhan O, Lee W-S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Ali MA, Cohen JI, et al. Effect of bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–189.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Heineman TC, Lal H, ZOE-50/70 Study Group, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–1760.
   PubMed Web of Science ®Google Scholar
• Zent CS, Brady MT, Delage C, et al. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia. 2020;35:1788–1791. Available from: http://www.nature.com/articles/s41375-020-01074-4
   PubMed Web of Science ®Google Scholar
• Muchtar E, Koehler AB, Johnson MJ, et al. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American J Hematol. 2022;97(1):90–98.
   PubMed Web of Science ®Google Scholar
• Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–84.
   PubMed Web of Science ®Google Scholar
• McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136(9):660–6.
   Google Scholar
• Parikh SA, Rabe KG, Kay NE, et al. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014;99(1):140–147.
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia: short report. Br J Haematol. 2001;114(1):107–110.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a metaanalysis. JAMA. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, Bollig C, Henschke N, Sguassero Y, Nejstgaard CH, Menon S, Nguyen TV, Ferrand G, Kapp P, Riveros C, Ávila C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, Boutron I. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021; 3(3) 1–122.
   Google Scholar
• Patel R, Park J, Shah A, et al. COVID-19 and cancer patients. Cancer Med J. 2020;3(1):40–48.
   PubMedGoogle Scholar
• Patel R, Saif MW. Management of pancreatic cancer during COVID-19 pandemic: to treat or not to treat? JOP. 2020;21(2):27–28.
   PubMed Web of Science ®Google Scholar
• Abdul-Jawad S, Baù L, Alaguthurai T, et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell. 2021;39(2):257–275.e6.
   PubMed Web of Science ®Google Scholar
• Clinical Guidance for Covid-19 Vaccination. Centers for disease control and prevention. centers for disease control and prevention. 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-consideration-us.html
   Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME. Whole inactivated virus and Protein-Based COVID-19 vaccines. Annu Rev Med. (January2022;73(1):55–64.
   PubMedGoogle Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARSCoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical Trial Group, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• heath pt, galiza ep, baxter DN, 2019ncov-302 study group, et al. Safety and efficacy of nvx-cov2373 covid-19 vaccine. 23. N engl J med. 2021;385(13):1172–1183.
   PubMed Web of Science ®Google Scholar
• Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778.
   PubMed Web of Science ®Google Scholar
• Resman Rus K, Korva M, Knap N, et al. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820.
   PubMed Web of Science ®Google Scholar
• Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020;6(5):591–605.
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, Karolinska COVID-19 Study Group, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168.e14.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2703–2705. http://www.nature.com/articles/s41375-021-01270-w.
   PubMed Web of Science ®Google Scholar
• Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and Meta-analysis. Blood Adv. 2022;6(7):2014–2034.
   PubMed Web of Science ®Google Scholar
• Greenberger LM, Saltzman LA, Senefeld JW, et al. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39(10):1297–1299. [Internet]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421105/.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against covid-19 in Israel. N Engl J Med. 2021;385(15):1393–1400.
   PubMed Web of Science ®Google Scholar
• Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–1246.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Rahav G, Levi S, Israeli CLL Study Group, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139(5):678–685.
   PubMed Web of Science ®Google Scholar